Category Archives: Genetics

Demand for Well-bred Animals With Desirable Genetic Traits to Drive Animal Genetics Market: Transparency Market Research – PRNewswire

ALBANY, New York, March 4, 2020 /PRNewswire/ -- Owing to multiple factors such as adoption of advanced technologies, high demand for well-bred animals with desirable genetic traits (livestock and poultry), and increase in disposable income is helping the global animal genetics marketchart a Compound Annual Growth Rate of 6.0 % from 2018 to 2026. As a result of this robust growth rate, market would be reach a valuation of USD 8.0 bn by the end of the forecast period.

Transparency Market Research states, "One of the most significant trends that will lead to a higher market growth over the forecast period is increase in ownership of companion animals. Besides, with food safety and quality gaining prominence, the live animal segment will show significant growth from 2018 to 2026."

Key Findings of the Animal Genetics Market Study

Explore 157 pages of top-notch research, incisive insights, and detailed country-level projections. Gain business intelligence on Animal Genetics market by Product Type - Live Animals (Bovine, Porcine, Poultry, Canine, and Piscine), Genetic Material (Semen, Embryo), Genetic Testing, Read Details TOC of the Report - https://www.transparencymarketresearch.com/report-toc/18995

Animal Genetics Market: Key Driving Factors

The animal genetics market is set to witness sturdy growth over the forecast period owing to a plethora of trends and growth drivers. As per Transparency Market Research, some of the crucial factors are high level of consumption of meat and poultry products, increase in purchasing power of people, need to plug supply gaps in terms of food, and growing demand for stronger animals, well-bred and with desirable genetic traits. An overview of growth factors is provided below:

Request PDF Brochure of Animal Genetics Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=18995

Key Impediments for Animal Genetics Market Players

Despite charting a steady growth curve over the forecast period, the global animal genetics market would not be free from restraints. As per Transparency Market Research, one of the major restraints that will limit growth in the global animal genetics market is the regulatory environment which is strict in terms of animal genetic engineering. Besides, a notable dearth of skilled professionals in the market is also a limiting factor in the global animal genetics market. Additionally, it is worth noting that animal testing is expensive.

Animal Genetics Market: Region-wise Analysis

Analyze Animal Genetics market growth in 30+ countries including US, Canada, Germany, United Kingdom, France, Italy, Russia, Poland, Benelux, Nordic, China, Japan, India, and South Korea. Request a sampleof the study,

Competition Landscape

Research and Development (R&D) forms the core of global animal genetics market and is thus a major determinant of the size of market share a player holds. Besides, players also forge partnerships in order to tap into uncharted territories in order to bring a larger consumer base into the fold. It is pertinent to note here that technology also holds a prominent place in the market.

Transparency Market Research has profiled key players such as Genus plc, CRV Holding B.V., Neogen Corporation Zoetis, Inc., Groupe Grimaud, Topigs Norsvin, VetGen, Animal Genetics Inc., and Hendrix Genetics BV, in its market report. The global animal genetics market has a decent number of players operating the market landscape.

Transparency Market Research has segmented the Animal Genetics market report based on product type, geography and forecast.

Product Type:

Explore Transparency Market Research's award-winning coverage of the Global Healthcare Industry:

Thyroid Function Test Market: The global thyroid function test market was valued at approximately US$ 1.3 Bn in 2018. It is anticipated to exceed a value of US$ 2.4 Bn by 2027, expanding at a CAGR of more than 5% from 2019 to 2027. The global market is driven by an increase in the incidence of thyroid disease, rise in geriatric population, increase in obese, diabetic, and cardiovascular patients, and increase in disease awareness programs in developing regions.

DNA Test Kits Market: The global DNA test kits market is driven by increase in the number of direct to consumer genetic testing companies offering DNA tests for ancestry and health & fitness, rise in focus on health risk & preventive care, and increase in demand for ancestry DNA testing services across the globe.

Audiological Devices Market: The global audiological devices market was valued at about US$ 8.7 Bn in 2017 and is expected to reach a value of US$ 13.4 Bn by 2026, expanding at a compound annual growth rate (CAGR) of over 5.0% from 2018 to 2026. The global market is witnessing expansion at a relatively higher growth rate owing to the increasing geriatric population, adoption of audiological devices due to rising number of cases of hearing loss, and surge in research and development in both developed and developing markets.

Laser Capture Microdissection Market: Increasing expenditure on healthcare along with technological advancement in the field of healthcare is one of the major driving factors for the laser capture microdissection market. Furthermore, increasing information regarding the technical advantages obtained from laser-capture microdissection techniques is fueling the market at the global level.

Gain access to Market Ngage, an AI-powered, real-time business intelligence that goes beyond the archaic research solutions to solve the complex strategy challenges that organizations face today. With over 15,000+ global and country-wise reports across 50,000+ application areas, Market Ngage is your tool for research on-the-go. From tracking new investment avenues to keeping a track of your competitor's moves, Market Ngage provides you with all the essential information to up your strategic game. Power your business with Market Ngage's actionable insights and remove the guesswork in making colossal decisions.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key tohelp enterprises reach right decision."

Contact

Transparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: [emailprotected]

Website: http://www.transparencymarketresearch.com

SOURCE Transparency Market Research

Continued here:
Demand for Well-bred Animals With Desirable Genetic Traits to Drive Animal Genetics Market: Transparency Market Research - PRNewswire

Leading National Genetics Foundation to Present Adapted Bikes to San Antonio-Area Children with Genetic Conditions – Herald-Mail Media

BETHESDA, Md., March 2, 2020 /PRNewswire/ -- The ACMG Foundation for Genetic and Genomic Medicine and genetics professionals from around the world will be on hand Friday, March 20th from 10:30 11:00 AM in the Henry B. Gonzlez Convention Center in San Antonio, Texas to present bicycles to local San Antonio-area children from the Sickle Cell Association of Texas Marc Thomas Foundation and the Down Syndrome Association of South Texas as part of the 2020 ACMG Annual Clinical Genetics Meeting.

The annual ACMG Foundation Day of Caring is sponsored by the ACMG Foundation for Genetic and Genomic Medicine, a prominent national nonprofit genetics foundation based in Bethesda, Maryland.

DeAnna Navarro, administrator and community health worker with the Sickle Cell Association of Texas Marc Thomas Foundation, said, "Our hearts are filled with gratitude by the thoughtfulness of the ACMG Foundation. We are genuinely grateful to have been selected to partner in the 2020 Day of Caring! The customized bicycles will provide ideal activity for children affected by sickle cell disease that is low-impact and therapeutic. We are excited that this gesture will help to bring a sense of normalcy to their lives."

Nicole Galindo, development manager at Down Syndrome Association of South Texas (DSASTX), said, "We are so grateful and ecstatic to be participating in ACMG's Day of Caring this year. The DSASTX is beyond thankful to have been chosen to receive these awesome bicycles for some of our awesome families. Having a bike that is custom fitted to each child provides such fun, gets them outdoors and can be seen as a confidence booster."

"We all look forward to the Day of Caring event as a way to express our respect for patients and families who deal with genetic conditions every day. We are grateful to our sponsors and to our members for making this event possible," said Bruce R. Korf, MD, PhD, FACMG, president of the ACMG Foundation.

The ACMG Foundation for Genetic and Genomic Medicine, whose theme is Better Health through Genetics, supports education, research and a variety of other programs to translate genetic research into better health for all individuals. The ACMG Foundation 2020 Day of Caring is supported by PerkinElmer, members of the American College of Medical Genetics and Genomics (ACMG), and the ACMG Foundation for Genetic and Genomic Medicine.

Note to assignment desks, news desks and editors: This is a wonderful photo, television and video opportunity. To arrange interviews with experts in medical genetics, local San Antonio-area families participating in the 2020 Day of Caring or to receive a complimentary pass to attend and cover the ACMG Annual Clinical Genetics Meeting, March 17-21, 2020 at the Henry B. Gonzlez Convention Center, contact Kathy Moran, MBA, ACMG senior director of public relations, at kmoran@acmg.net.

About the ACMG Foundation for Genetic and Genomic Medicine

The ACMG Foundation for Genetic and Genomic Medicine, a 501(c)(3) nonprofit organization, is a community of supporters and contributors who understand the importance of medical genetics and genomics in healthcare. Established in 1992, the ACMG Foundation supports the American College of Medical Genetics and Genomics (ACMG) mission to "translate genes into health." Through its work, the ACMG Foundation fosters charitable giving, promotes training opportunities to attract future medical geneticists and genetic counselors to the field, shares information about medical genetics and genomics, and sponsors important research. To learn more and support the ACMG Foundation mission to create "Better Health through Genetics" visit http://www.acmgfoundation.org.

Kathy Moran, MBAkmoran@acmg.net

Continue reading here:
Leading National Genetics Foundation to Present Adapted Bikes to San Antonio-Area Children with Genetic Conditions - Herald-Mail Media

UPDATED: Vertex, Seattle Genetics, Alpine withdraw from investor conference as biotechs brace for coronavirus – Endpoints News

Speed is of the essence when it comes to developing vaccines and therapeutics for the new coronavirus. Especially if you are briefing President Donald Trump.

Whats your timing here? was Trumps go-to question after he listened to each of the 10 biopharma executives who convened in the White House Monday afternoon with the coronavirus task force led by VP Mike Pence.

The usual suspects were present: Stphane Bancel of Moderna, which has shipped off its mRNA vaccine for a Phase I study at the NIH; Len Schleifer of Regeneron, in the hunt for antibodies; Gileads Daniel ODay, there to discuss the two Phase III trials his company has started for a closely watched antiviral; and GlaxoSmithKline CEO Emma Walmsley, together with representatives of J&J and Sanofi, representing the traditional vaccine makers.

Unlock this story instantly and join 73,500+ biopharma pros reading Endpoints daily and it's free.

SUBSCRIBE SIGN IN

Read more:
UPDATED: Vertex, Seattle Genetics, Alpine withdraw from investor conference as biotechs brace for coronavirus - Endpoints News

USDA grant supports potato breeding and genetics program – MSUToday

Michigan State University received $700,000 from the U.S. Department of Agricultures National Institute of Food and Agriculture to invest in its potato breeding and genetics program.

The award is part of a $2.25 million four-part grant to support potato breeding in strategic areas across the country, which includes partnering institutions University of Minnesota, North Dakota State University and the University of Wisconsin.

Potato production in Michigan, Minnesota, North Dakota and Wisconsin accounts for nearly a quarter of U.S. potato acreage and a farmgate value of $982.5 million. The North Central region which also includes Illinois, Indiana, Iowa, Kansas, Missouri, Nebraska, Ohio and South Dakota is responsible for the most potato production outside of the Pacific Northwest.

Dave Douches, a professor in the MSU Department of Plant, Soil and Microbial Sciences, has led the MSU potato breeding and genetics program for nearly 30 years. The program has produced nearly 30 new potato varieties. The most recent, Blackberry, is a purple-fleshed variety that took more than 20 years to develop. It is resistant to potato scab and has high antioxidant levels.

This is a new round of funding for our long-term genetics work to help us interact with growers and develop new varieties, Douches said. The USDA has supported these efforts with multiple grants. The advancements weve made wouldnt be possible without this support.

The grant proposal outlines the following objectives:

Douches said that geneticists are looking not only to improve varieties for growers by focusing on disease and pest resistance, but also to meet consumer demand. Enhanced nutritional profiles are a crucial aspect of the research.

Weve been most known for producing potatoes that go into snacks such as potato chips, Douches said. Thats been important to us, but the companies were working with want to explore how we can improve the nutritional properties of our varieties. This can help us make snacking healthier, and all of our partners from growers to companies have shown interest in that.

Read more from the original source:
USDA grant supports potato breeding and genetics program - MSUToday

Lawson team wins $4.8M to test made-in-London genetic disease screening tool – The London Free Press

Dr. Bekim Sadikovic. (File photo)

London researchers have won a $4.8-million in funding to test a locally developed screening tool that can help doctors pinpoint difficult-to-diagnose genetic disorders.

The funding will let a team at Lawson Health Research Institute, the research arm of Londons hospitals, undertake three or four years of clinical studies of EpiSign technology.

At this point, we can use this technology to test for almost 50 different conditions, said Bekim Sadikovic, the Lawson scientist who heads London Health Sciences Centres molecular genetics division. Weve been studying this technology to see how far it reaches and how many disorders we can help ultimately diagnose with it.

The research team will recruit 4,000 patients from across Canada for the study. Since EpiSign tests for neurodevelopmental conditions typically noticed in early childhood, most study participants will be younger kids, Sadikovic said.

Detecting some genetic disorders is straightforward: Researchers analyze a patients DNA, comparing it to normal genetic material to find any abnormal genes and make a diagnosis, he said.But sometimes, patents who likely have genetic disorders also have normal DNA structures, sending them on a diagnostic odyssey in search of answers and treatment.

One of the big challenges has been diagnosing these patients, Sadikovic said. Currently we do fairly broad genetic and genomic testing and generally speaking, at best, our diagnostic rate in this population is about 50 per cent.

The teams EpiSign technology takes a deeper look at DNA, examining epigenomes that switch certain genes on and off.Some patients have normal DNA structure, but abnormal epigenomes. The team has pinpointed epigenetic signatures of nearly 50 rare genetic diseases, including developmental and intellectual disabilities such as Fragile X, Angelman and Kabuki syndromes.

With the EpiSign test, doctors draw blood from a patient, examine the DNA and epigenomes and compare the findings to a database of results from thousands of patients curated by London researchers.

The multi-year study will see if there are benefits to using EpiSign as a first-line diagnostic tool.Researchers will see if the new test produces quicker diagnoses, reduces the need for other tests and helps cut health-care costs, Sadikovic said.

The team also aims to increase the number of disorders it can detect.

The research project is funded by LHSC, Illumina, a California-based biotech firm, and Genome Canada, a federally funded national non-profit supporting gene research and technology.

jbieman@postmedia.com

twitter.com/JenatLFPress

More here:
Lawson team wins $4.8M to test made-in-London genetic disease screening tool - The London Free Press

Building ‘better’ astronauts through genetic engineering could be key to colonizing other planets – Genetic Literacy Project

Space exploration has long been a source of fascination. Since the stars first captured our attention, we have obsessed over that vast curtain of darkness that lies beyond our atmosphere. But to what end? What ultimate goal does mankind strive towards, if not the ability to visit and colonize other worlds?

Before we can take our first steps out into the universe, we have to answer a critical question: Do we have the ability to adapt to other environments very different from what we have on Earth to not only survive, but to thrive? Instead of focusing on how we might terraform other planets to suit us, perhaps we should consider how we might use genetic engineering to alter own bodies to suit those other planets.

As a jumping off point, lets consider the feasibility of using the popular gene-editing tool CRISPR to alter human physiology to tolerate parameters outside of Earths norms. If we take a look at common factors that are significant to human health, gleaned from our experience with space exploration, the most obvious choices for our attention are variations in gravity, atmospheric pressure and gas ratios, and solar radiation levels.

If we consider Mars as our template, because of its relative suitability for colonization, then we must compensate for two-thirds less gravity than Earth. A lack of gravity results in a number of ill effects on human health, including a decrease in bone mass and density over time, particularly in the large bones of the lower extremities, as well as the spine. While we do not have research showing the impact of living on a planet with one-third Earths gravity, we do know that we can expect losses in bone density somewhere under 1-2 percent per month, the amount lost in the microgravity environment of space.

For comparison, the elderly lose 1-1.5 percent per month in Earth gravity. Atmospheric pressure that is either too high or too low also results in complications; low atmospheric pressure results in less oxygen available and causes altitude sickness and possible death. Radiation levels from the sun are another variable that is well known to have upper and lower thresholds for optimal human health, where low levels can lead to vitamin D deficiency and high levels increase cell death and cancer.

It would stand to reason that the human body has a minimum threshold for healthy physiology as regards the environment in which it grows, develops and lives. To colonize other planets successfully, we must consider solutions to overcome these thresholds; for example: prostheses, domed colonies recreating an ideal or near ideal environment, or, as this author suggests, the permanent genetic alteration of humanity as a species. This applies to our four chosen variables of gravitational forces, atmospheric pressure, atmospheric gas ratios, and solar radiation levels. While science fiction might have us consider surgical and biomedical prostheses or the more far-fetched use of animal DNA to change ourselves for this purpose, the key to human adaptation for other planets lies in our own genetics and it may well be CRISPR, the use of the enzyme Cas9 for introduction of altered DNA sequences or CRISPRs to existing cells to change how those cells function, that will make this possible.

Human genetic variation provides a veritable treasure trove of adaptations if one looks at the less common but heritable variations that on Earth may seem irrelevant, nonessential, or even maladaptive, but on another planet could be essential to survival. One example of a gene that, with engineering, could help humanity adapt to higher or lower gravity is the LRP5 gene. Recent research into the LRP5 gene shows that mutations of the gene are responsible for both low bone density and elevated bone density in the case of the later, from increased bone formation. A family of individuals in Nebraska carrying the mutation for elevated bone density have never experienced broken bones even well into old age. A whole colony of such individuals or ones engineered to enhance this mutation further could be expected to fare much better during prolonged space travel in zero gravity as well as in the low gravity environment on a planet like Mars.

While an atmospheric pressure and gas makeup very similar to Earths would be required for humans to survive and thrive outside of a spacesuit, Nepals Sherpas, high altitude dwellers in Ethiopia, and the Collas people in the Central Andes , as well as the deep sea divers of Bajau, may provide a solution to living on planets with differences in atmospheric pressure and oxygen availability. The three groups of high-altitude dwellers appear to have separate adaptations for thriving in low oxygen environments. Recent research indicates that there are genetic mutations in each of these groups. Sherpas mutations allow for more efficient use of available oxygen and resistance to ill effects from hypoxia.

Sherpas experience less of an increase in red blood cells than others and therefore avoid the ill-effects caused, such as edema and brain swelling. Sherpas instead have mitochondria in their cells that make more efficient use of the available oxygen, as well as having more efficient anaerobic metabolism in the absence of oxygen. The Collas show genetic differences in genes that control heart morphology, as well as cerebral vascular flow, as a means to withstand an elevated hematocrit in response to high altitude living. The Amhara people living in high altitudes in Ethiopia unlike the Sherpas do have lower oxygen saturation and higher hemoglobin levels compared to lowland dwellers in the region.

Research has yet to determine what adaptation favors the Amhara, but several genes that may play a role have been isolated. Another group, the Bajau of Thailand, may have complementary genetic variations that help them resist hypoxia and survive the high pressures of deep sea diving. Researchers found them to have 50% larger spleens and also a gene, PDE10A, that controls a thyroid hormone thought to affect spleen size. Capitalizing on any of these genetic features would improve our ability to survive with a lower oxygen content atmosphere, perhaps on a newly terraformed Mars or under domes with oxygen rationing.

While we cannot yet determine how comparable an atmosphere we can create on Mars, it stands to reason that achieving an exact replica atmosphere to Earths could be difficult. An atmosphere that lets in less radiation could impede our production of vitamin D, while a thinner atmosphere would admit an excess of radiation. Vitamin D deficiency could perhaps be handled by supplementation, or instead addressed by increasing our cells response to ultraviolet light to increase vitamin D synthesis. On the other side of the coin, a thinner atmosphere opens us up to higher UVR, which would result in higher rates of skin cancer.

It would stand to reason that, while skin pigmentation has high cultural and historical significance, it could make our species more suitable for colonization of high radiation planets; darker skin with larger melanocytes that react proactively to UVA and UVB radiation through tanning and higher antioxidant and free-radical counteraction would be protective and provide an advantage if we are to branch out into our solar system and beyond. At the same time, this solution poses the problem of vitamin D production.

The answer could lie in isolating and using the genes responsible for East Asian populations lower skin pigmentation coupled with lower skin cancer rates than European populations. A study headed by Pennsylvania university has isolated gene mutations responsible for skin pigmentation differences, SLC24A5, MFSD12, OCA2, and HERC2, by studying African, South Asian Indian, and Australo-Melanesian populations, some of which are associated with vitiligo and a form of albinism common in African populations. These mutations that confer higher vitamin D production to Europeans are not present in East Asians, indicating a different mutation responsible, and, while both populations have higher vitamin D production than African populations, Europeans have a 10-20 percent higher rate of cancer than both Africans and East Asians. Further research into these genes could provide targets for CRISPR to modify the protective factors in our skin without sacrificing vitamin D production of potential colonists.

The question remains: is CRISPR a feasible route to including some of these adaptations to create a new, more suitable colonist? To answer this question we look at the current status of CRISPR research.

While some experiments using CRISPR gene editing were conducted in the technologys infancy, including the controversial creation of twin girls in China designed to be resistant to HIV, we are still quite a bit of research away from using CRISPR with high success rates and full confidence, especially considering the repercussions of rushing into human trials, including the death of trial participants and long-term side-effects of cancer, both of which have occurred in gene-therapy trials.

According to information revealed by the FDA and NIH, 691 trial volunteers died in gene-editing trials prior to the tragic and high-profile death of Jesse Gelsinger in a 1999 trial to treat his OTCD, a rare metabolic disorder. The death was blamed on ethical oversights and a rush to make gene editing pan out before it was ready. The result was a long period of gene-editing fear and oversight but also, in the case of James Wilson, director of the University of Pennsylvanias Institute for Human Gene Therapy responsible for the trials that led to Gelsingers death, greater caution in research methodology. He has put safety at the forefront of his research and asserts that even still the risks of gene editing with CRISPR and other methods brings enough risk to justify human trials only for those diseases that are severe and debilitating enough for patients to accept the risks of gene editing.

What does all this mean for our hypothetical future of using CRISPR to edit the DNA of human colonists for space colonization? Is the technology too far off to serve our purpose or fraught with too much risk? Is it beyond our knowledge and skill to accomplish? The answer to each of these questions is undoubtedly, no.

Weve had too much success in treating complex genetic conditions, like the creation of an immune system for Ashanthi Desilva born with severe combined immunodeficiency (SCVID). Weve unlocked too many keys to making gene therapy safer and more effective to discount the possibility of future use for the advancement of our species into harsher environments. While subsequent uses of gene therapy for SCVID resulted in development of Leukemia years later, further advancements in the research have revealed the need to find the best delivery system for each body system. Adeno-associated viruses, and lentiviruses are being looked at in place of the more aggressive adenovirus or retroviruses for delivery of DNA segments both of which are less likely to provoke an immune response and less likely to trigger cell death by way of the B35 gene in healthy cells, and later cancer.

Regardless of the work ahead and the bumpy road that gene therapy has traveled, vast potential remains at our fingertips whether it is through use of CRISPR or future gene therapy tools. It is a sure eventuality that we will one day have these skills at the ready to spread our species into other worlds, well-equipped to survive and thrive in harsher environments.

Cherrie Newman is a writer and student of human reproduction and biological sciences. She is the author of a science fiction novel series entitled Progeny under the pseudonym CL Fors. Follow her on her blogor on Twitter @clfors

Read more:
Building 'better' astronauts through genetic engineering could be key to colonizing other planets - Genetic Literacy Project

BRIEF-Seattle Genetics Announces Cancellation Of Presentation And Webcast At The Cowen 40th Annual Healthcare Conference – Reuters

March 2 (Reuters) - Seattle Genetics Inc:

* SEATTLE GENETICS ANNOUNCES CANCELLATION OF PRESENTATION AND WEBCAST AT THE COWEN 40TH ANNUAL HEALTHCARE CONFERENCE

* SEATTLE GENETICS - WILL NO LONGER BE ATTENDING CONFERENCE AS A PRECAUTIONARY MEASURE RELATED TO TRAVEL AMIDST EVOLVING CORONAVIRUS SITUATION Source text for Eikon: Further company coverage:

See more here:
BRIEF-Seattle Genetics Announces Cancellation Of Presentation And Webcast At The Cowen 40th Annual Healthcare Conference - Reuters

Researchers dive deep into the genetic legacy of the transatlantic slave trade – ZME Science

Print showing an alleged incident of an enslaved African girl whipped to death for refusing to dance naked on the deck of the slave shipRecovery, a slaver owned by Bristol merchants. Captain John Kimber was denounced before the House of Commons by William Wilberforce over the incident. In response to outrage by abolitionists, Captain Kimber was brought up on charges before the High Court of Admiralty in June 1792, but acquitted of all charges. Credit: United States Library of Congresss Prints and Photographs division.

Researchers in Brazil combined historical and genetic data to reveal new insights about the transatlantic slave trade that saw more than 9 million Africans shipped in chains to the Americans from the early 16th century until the mid-19th century. The findings suggest that the African populations imported their genetic diversity and spread their mutations in the Americas through admixture with indigenous and European populations.

We know in the Americas that the slave trade was a human tragedy, but it is part of our history and identity. This is why my group, but mainly myself and my former PhD student Mateus Gouveia focused in the African Diaspora, Eduardo Tarazona-Santos, a researcher at the Federal University of Minas Gerais in Brazil and lead author of the new study, told ZME Science.

African populations are the most diverse in the world, genetically speaking. Tarazona worked closely with colleagues in Brazil, Peru, and the United States to assemble what he calls the largest up-to-date dataset of Americas and African genetic data, which includes 6,267 individuals with more than 10% African ancestry from 25 populations.

Researchers compared the genetic data with historical demographic data from Slave Voyages database, which tracked and mapped the dispersal of enslaved Africa into the Americas.

We came out with a mathematical method that makes this comparison compatible. Then werealizedthat comparing genetic and historical-demography data is something modern geneticists had forgotten to do during the last 10-20 years, but it this kind of comparisons were more common before and have a solid tradition in human population genetics, since thework by Luca Cavalli-Sforza (who passed away in 2018) sixtyyears ago in the Parma Valley in Italy, where he compared genetic data (from blood groups) with parish record data. So recovering this kind of work, is like making a tribute to Luca Cavalli-Sforza. Reading his books has been an inspiration for many young investigators that in the nineties decided to dedicate to human population genetics, as I did, Tarazona said.

The researchers found that West Central African ancestry (from countries such as Nigeria and Ghana) is the most common in the Americas. West African ancestry (i.e. Senegal and Gambia) increases going northward while bantu ancestry (from south and southeast Africa) is more significant in the South of Brazil.

Historical records show that the transatlantic slave trade was at its height between 1750 and 1850. The new study found that this period also coincides with the most admixture between imported African populations and locals of European and indigenous ancestry. This timing implies that the 19th century was critical in shaping the structure of the African gene pool in the New World.

The African Diaspora was so massive (>9 million people), that the genetic diversity observed in the African portions of our admixed genomes is similar to that of African populations of origin of slavery. However, admixture homogenized this diversity (and the mutations responsible for diseases) between the different populations of the African continent, Tarazona told ZME.

All in all, the study provides unique insights into the gene flow caused by the massive transatlantic slave trade, whose influence is still important in todays social and cultural setting in the Americas.

Our results imply that the Africans imported most of their genetic diversity, including the mutations responsible for the diseases, and that admixture has spread these mutations in the Americas along most of the continent. In Africa, they are more compartmentalized geographically. This is important when we interpret data about where there are in the Americas mutations responsible for diseases such as cystic fibrosis and hereditary cancer, Tarazona concluded.

The findings appeared on March 2 in the journal Molecular Biology and Evolution.

More:
Researchers dive deep into the genetic legacy of the transatlantic slave trade - ZME Science

Riding the Trend or Protecting Profits: Seattle Genetics, Inc. (SGEN) – The News Heater

Seattle Genetics, Inc. (NASDAQ:SGEN) went down by -1.74% from its latest closing price when compared to the 1-year high value of $124.32 and move down -11.12%, while SGEN stocks collected -3.55% of loss with the last five trading sessions. Press Release reported 15 hours ago that Seattle Genetics Announces Cancellation of Presentation and Webcast at the Cowen 40(th) Annual Healthcare Conference

Seattle Genetics, Inc. (NASDAQ: SGEN) The 36 Months beta value for SGEN stocks is at 1.80, while of the analysts out of 0 who provided ratings for Seattle Genetics, Inc. stocks as a buy while as overweight, rated it as hold and as sell. The average price we get from analysts is $127.80 which is $13.87 above current price. SGEN currently has a short float of 2.91% and public float of 170.23 M with average trading volume of 1.10M shares.

SGEN stocks went down by -3.55% for the week, with the monthly jump of 1.83% and a quarterly performance of -7.55%, while its annual performance rate touched 49.81%. The simple moving average for the period of the last 20 days is -3.12% for SGEN stocks with the simple moving average of 22.98% for the last 200 days.

Many brokerage firms have already submitted their reports for SGEN stocks, with Barclays repeating the rating for SGEN shares by setting it to Equal Weight. The predicted price for SGEN socks in the upcoming period according to Barclays is $124 based on the research report published on February 18, 2020.

H.C. Wainwright, on the other hand, stated in their research note that they expect to see SGEN stock at the price of $150, previously predicting the value of $140. The rating they have provided for SGEN stocks is Buy according to the report published on February 12, 2020.

Goldman gave Buy rating to SGEN stocks, setting the target price at $165 in the report published on February 11, 2020.

After a stumble in the market that brought SGEN to its low price for the period of the last 52 weeks, Seattle Genetics, Inc. was unable to take a rebound, for now settling with -10.01% of loss for the given period.

The stock volatility was left at 4.45%, however, within the period of a single month, the volatility rate increased by 7.09%, while the shares surge at the distance of +3.22% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by -1.17% lower at the present time.

In the course of the last 5 trading sessions, SGEN went down by -3.55%, which changed the moving average for the period of 200 days to the total of +74.84% of gains for the stock in comparison to the 20-day moving average settled at $115.65. In addition, Seattle Genetics, Inc. saw -2.08% in overturn over the period of a single year with a tendency to cut further losses.

Reports are indicating that there were more than several insider trading activities at Seattle Genetics, Inc. (SGEN), starting from DANSEY ROGER D, who sold 350 shares at the price of $116.33 back on Feb 18. After this action, Rushing now owns 107,659 shares of Seattle Genetics, Inc., valued at $40,716 with the latest closing price.

SIEGALL CLAY B, the President and CEO of Seattle Genetics, Inc., sold 28,472 shares at the value of $114.61 during a trade that took place back on Feb 10, which means that SIEGALL CLAY B is holding 758,784 shares at the value of $3,263,110 based on the most recent closing price.

The current profitability levels are settled at -24.06 for the present operating margin and +95.21 for gross margin. The net margin for Seattle Genetics, Inc. stands at -17.31. Total capital return value is set at -13.67, while invested capital returns managed to touch -9.86. Equity return holds the value -10.20%, with -8.50% for asset returns.

Based on Seattle Genetics, Inc. (SGEN), the companys capital structure generated 4.11 points for debt to equity in total, while total debt to capital is set at the value of 3.94.

The value for Enterprise to Sales is 21.39 with debt to enterprise value settled at 0.00. The receivables turnover for Seattle Genetics, Inc. is 4.80 with the total asset turnover at the value of 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.54.

See the article here:
Riding the Trend or Protecting Profits: Seattle Genetics, Inc. (SGEN) - The News Heater